OPK · XBRL financial data

OPKO Health financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OPK's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,435	1,775	1,004	863	713	607
Cost of goods and services sold	—	—	716	545	495	401
Gross profit	—	—	288	318	219	206
Research and development	75	77	74	90	105	124
Selling, general and administrative	356	469	373	301	304	223
Total operating expenses	1,378	1,756	1,230	1,021	—	—
Operating income (loss)	58	19	(226)	(157)	(152)	(117)
Interest income	—	0	2	4	8	15
Interest expense	—	19	12	14	47	0
Other income (expense)	13	(15)	(156)	(17)	207	(30)
Income tax expense (benefit)	18	15	(63)	4	43	(16)
Net income (loss)	31	(30)	(328)	(189)	(53)	(226)
Earnings per share, basic USD per share	0.05	(0.05)	(0.46)	(0.25)	(0.08)	(0.30)
Earnings per share, diluted USD per share	0.05	(0.05)	(0.46)	(0.25)	(0.08)	(0.30)
Weighted average shares, basic millions of shares	641	648	719	752	694	751
Weighted average shares, diluted millions of shares	641	648	719	752	694	751

Fiscal years (OPK's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	72	135	153	96	427	364
Accounts receivable	286	260	127	123	118	90
Inventory	132	87	74	66	57	66
Prepaid and other current assets	32	27	40	25	55	57
Total current assets	523	823	395	309	662	582
Property and equipment, net	141	—	83	75	70	74
Right-of-use asset	38	44	39	68	54	47
Goodwill	681	521	596	598	529	484
Total assets	2,473	2,400	2,167	2,012	2,200	1,932
Accounts payable	101	82	67	70	47	41
Accrued liabilities	241	193	98	90	118	84
Current portion of long-term debt	—	—	2	2	1	344
Total current liabilities	375	330	213	200	193	147
Long-term debt	4	—	9	8	3	2
Lease liability, non-current	30	33	28	54	49	37
Total liabilities	802	715	606	622	835	664
Accumulated deficit	(1,482)	(1,512)	(1,823)	(2,012)	(2,065)	(2,291)
Total stockholders' equity	1,672	1,685	1,562	1,389	1,365	1,268
Total liabilities and equity	2,473	2,400	2,167	2,012	2,200	1,932
Common shares outstanding (cover page) millions of shares	670	681	773	697	672	759

Fiscal years (OPK's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	31	(30)	(328)	(189)	(53)	(226)
Stock-based compensation	9	14	19	11	11	11
Depreciation and amortization	85	79	109	105	98	92
Net cash from operating activities	39	38	(95)	(28)	(183)	(179)
Net cash from investing activities	(18)	36	91	(18)	352	230
Proceeds from issuing common stock	0	0	—	—	—	—
Share repurchases	—	—	0	0	90	47
Net cash from financing activities	(35)	(10)	23	(11)	184	(118)
Net change in cash	(13)	62	18	(57)	350	(63)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Opko Health	384	65	(36)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Iovance Biotherapeutics	111	99	(61)*	453.0M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Savara	42	not reported	(30)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Xencor	60	117	2.6*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Evolus	42	78	(1.9)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
KalVista Pharmaceuticals	214	41	(14)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
Kura Oncology	70	21	(63)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Trevi Therapeutics	54	not reported	(17)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.